GILDD

Gilead Sciences BASE:GILDD Stock Report

Last Price

US$21.90

Market Cap

US$108.2b

7D

-0.5%

1Y

15.0%

Updated

15 Jan, 2023

Data

Company Financials +

GILDD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILDD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$21.90
52 Week HighUS$22.00
52 Week LowUS$14.50
Beta0.43
1 Month Change2.10%
3 Month Change26.59%
1 Year Change14.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-98.47%

Recent News & Updates

Recent updates

Shareholder Returns

GILDDAR BiotechsAR Market
7D-0.5%0%0%
1Y15.0%0%0%

Return vs Industry: GILDD exceeded the AR Biotechs industry which returned -4.6% over the past year.

Return vs Market: GILDD underperformed the AR Market which returned 165.9% over the past year.

Price Volatility

Is GILDD's price volatile compared to industry and market?
GILDD volatility
GILDD Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in AR Market0%
10% least volatile stocks in AR Market0%

Stable Share Price: Insufficient data to determine GILDD's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine GILDD's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILDD fundamental statistics
Market CapUS$108.20b
Earnings (TTM)US$3.33b
Revenue (TTM)US$27.14b

32.5x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILDD income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did GILDD perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

109%

Payout Ratio